4 results about "Induction therapy" patented technology

Disclosed is the use of a composition comprising a TET pathway inhibitor and a ferroptosis inducer in the manufacture of a medicament for the treatment of malignant tumors. It is found that TET1 up-regulates expression of a ferroptosis key regulation gene GCH1 through an NF [kappa] B signal, promotes synthesis of BH4, activates a GPX4 non-dependent pathway, and plays a key hub role in controlling ferroptosis sensitivity. Through combined use of TET pathway inhibitors (including a TET inhibitor and a BH4 synthesis inhibitor), the sensitivity of tumor cells to the ferroptosis inducer can be significantly improved, and the in-vivo use dosage of the ferroptosis inducer is reduced to 1% (1 mg / kg) of the conventional treatment dosage. The composition of the TET pathway inhibitor and the ferroptosis inducer, provided by the invention, can be used for remarkably improving the ferroptosis induction curative effect of various malignant tumors, particularly ferroptosis insensitive tumors, and enhancing the safety and universality of ferroptosis induction treatment.

This invention discloses the application of fruquintinib combined with PD-1 monoclonal antibody in maintenance therapy for HER-2 negative advanced gastric cancer / geoesophageal junction adenocarcinoma, belonging to the field of tumor treatment technology. This invention targets HER2-negative advanced gastric cancer or gastroesophageal junction adenocarcinoma, specifically patients who achieve disease control after 3 months of first-line induction therapy with PD-1 monoclonal antibody combined with oxaliplatin, followed by maintenance therapy with fruquintinib combined with PD-1 monoclonal antibody without chemotherapy. The maintenance therapy regimen provided by this invention improves patients' quality of life and prolongs overall survival while delaying disease progression, and has significant clinical implications.

Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and / or maintenance therapy.

The application provides a kind of drug composition in the preparation for the application of the drug for the maintenance treatment of disease control ES-SCLC after first-line chemotherapy, belong to the biomedicine technical field.The drug composition is carimab and apatinib.The application finds that carimab is combined with apatinib as maintenance treatment, shows encouraging efficacy and acceptable safety in ES-SCLC patient who is not in progress after first-line chemotherapy, the median overall survival (OS) is 25.00 months, and the 12-month OS rate is 71.4%.This strategy of simultaneously targeting PD-1 and VEGFR2 provides a novel and reasonable solution for extending the disease control period in malignant tumors with limited treatment options after induction therapy, not only solves the key needs of ES-SCLC patients for more effective maintenance treatment, but also provides important insights into the biological principles of anti-angiogenic therapy combined with immunotherapy.